Shots:

• The NMPA’s approval is based on P-III PINNACLE 4 study assessing Bevespi Aerosphere (bid via a pMDI) vs its monotherapy components (glycopyrronium and formoterol fumarate) and PBO in patients with moderate to very severe COPD
• The P-III PINNACLE 4 study demonstrated improvement in lung function as measured by trough forced expiratory volume in one second (FEV1)- published in the International Journal of Chronic Obstructive Pulmonary Disease
• The approval follows the approval of AstraZeneca’s triple-combination therapy- Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) for the maintenance treatment of COPD in China. Bevespi Aerosphere (FD) is a dual bronchodilator- administered in a pressurized metered-dose inhaler utilizing Aerosphere delivery technology

Click here ­to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca